Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (38)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fliser, D.
Right arrow Articles by Ritz, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fliser, D.
Right arrow Articles by Ritz, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 12, Issue 5 933-938, Copyright © 1997 by Oxford University Press


ORIGINAL ARTICLES

Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans

D Fliser, E Franek, P Fode, A Stefanski, C Schmitt, M Lyons and E Ritz
Departments of Internal Medicine and Pediatrics, Ruperto-Carola University, Bergheimstrasse 56a, 69115 Heidelberg, Germany; Corresponding author

Background. Acute administration of parathyroid hormone (PTH) causes vasodilation and blood pressure decrease in experimental animals. This effect contrasts with the putative role of secondary hyperparathyroidism in the pathogenesis of hypertension of patients with renal failure. Uraemia is characterized by insulin resistance and hyperinsulinaemia. We therefore investigated whether subacute administration of physiological doses of human 1,34-PTH affects blood pressure under conditions of controlled insulin levels (euglycaemic clamp technique) in humans. Methods. In a double-blind cross-over design 10 healthy male subjects received, on two occasions, in random order, for 2 h, either a sham infusion or an infusion of 200 units of 1,34-PTH. Results. Mean ionized calcium concentration increased significantly (P <0.01) within the normal range during euglycaemic hyperinsulinaemia, both with sham infusion (from 1.25 ± 0.04 to 1.29 ± 0.02 mmol/l) and with infusion of 1,34-PTH, but the increase was more marked with 1,34-PTH administration (from 1.26 ± 0.05 to 1.33 ± 0.07). In addition, mean platelet intracellular calcium concentration (by fluorescence spectroscopy) was unchanged with sham infusion (49.9 ± 4.1 versus 50.3 ± 5.0 nmol), but increased significantly (P <0.05; paired t-test) after 1,34-PTH infusion (from 49.8 ± 5.0 to 52.8 ± 5.8). The infusion of 1,34-PTH resulted in a significant (P <0.01) increase in mean MAP (from 84 ± 5 to 88 ± 5 mmHg) as compared with sham infusion (85 ± 4 versus 86 ± 4). The intra-individual changes in intracellular calcium concentration (&Dgr;[Ca2+]I) were significantly correlated to the changes in mean MAP (&Dgr;MAP) (r = 0.87, P <0.001). In contrast to blood pressure, insulin sensitivity was not affected by 1,34-PTH infusion (M-value: 7.2 ± 1.6 mg/kg per min) as compared with sham infusion (7.3 ± 1.4). Conclusion. Subacute administration of physiological doses of parathyroid hormone under hyperinsulinaemic conditions significantly affects intracellular calcium and blood pressure in healthy subjects, but does not affect the action of insulin. Keywords: parathyroid hormone; blood pressure; euglycaemic clamp; hypertension; hyperparathyroidism; insulin sensitivity; intracellular calcium
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
T. Odenwald, K. Nakagawa, C. Hadtstein, F. Roesch, P. Gohlke, E. Ritz, F. Schaefer, and C. P. Schmitt
Acute Blood Pressure Effects and Chronic Hypotensive Action of Calcimimetics in Uremic Rats
J. Am. Soc. Nephrol., March 1, 2006; 17(3): 655 - 662.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
K. C Chiu
Reply to M Manco et al and to MF McCarty
Am. J. Clinical Nutrition, November 1, 2004; 80(5): 1452 - 1453.
[Full Text] [PDF]


Home page
Eur Heart JHome page
P. Andersson, E. Rydberg, and R. Willenheimer
Primary hyperparathyroidism and heart disease -- a review
Eur. Heart J., October 2, 2004; 25(20): 1776 - 1787.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
G. M. Chertow
Slowing the Progression of Vascular Calcification in Hemodialysis
J. Am. Soc. Nephrol., September 1, 2003; 14(90004): S310 - 314.
[Abstract] [Full Text]


Home page
J. Am. Soc. Nephrol.Home page
H. Ogata, E. Ritz, G. Odoni, K. Amann, and S. R. Orth
Beneficial Effects of Calcimimetics on Progression of Renal Failure and Cardiovascular Risk Factors
J. Am. Soc. Nephrol., April 1, 2003; 14(4): 959 - 967.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
D. C. Hatton, Q. Yue, J. Dierickx, C. Roullet, K. Otsuka, M. Watanabe, S. Coste, J. B. Roullet, T. Phanouvang, E. Orwoll, et al.
Calcium metabolism and cardiovascular function after spaceflight
J Appl Physiol, January 1, 2002; 92(1): 3 - 12.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Kosch, M. Hausberg, K. Vormbrock, K. Kisters, G. Gabriels, K. Heinz Rahn, and M. Barenbrock
Impaired flow-mediated vasodilation of the brachial artery in patients with primary hyperparathyroidism improves after parathyroidectomy
Cardiovasc Res, September 1, 2000; 47(4): 813 - 818.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
G. M. Chertow, S. K. Burke, M. A. Dillon, and E. Slatopolsky
Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients
Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2907 - 2914.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.